Skip to main content
. Author manuscript; available in PMC: 2023 Mar 22.
Published in final edited form as: Nat Nanotechnol. 2023 Jan 26;18(2):184–192. doi: 10.1038/s41565-022-01310-1

Figure 4. 3-drug BPD combination index (CI) studies.

Figure 4.

(A) CI maps obtained by using the Chou-Talalay method with a fixed dose of Dexamethasone (Dex, 2 nM) and by varying the concentrations of Btz and Pomalidomide (Pom) used in free drugs combinations (top); a fixed dose of Dex-BPD (20 nM) and varying Btz-BPD and Pom-BPD were employed for BPD combinations (bottom) after 48h of treatment. (B) Ratio validation using viability assays of 3-drug BPDs at Syn and Ant were performed in 4 MM cell lines (KMS11, MM.1S, U266, and KMS18), confirming that the selected ratios were synergistic and antagonistic in comparison to the Bliss model (for additive drug activity).